Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019

…, Y Fu, S Ge, L Liu, J Zhang, N Xia… - Clinical infectious …, 2020 - academic.oup.com
Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody
response in infected patients remains largely unknown, and the clinical value of antibody …

Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus

…, AQ Bakker, H Spits, T Beaumont, Z Zheng, N Xia… - science, 2013 - science.org
Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5
years of age. We sought to engineer a viral antigen that provides greater protection than …

[HTML][HTML] Methods favoring homology-directed repair choice in response to CRISPR/Cas9 induced-double strand breaks

…, S Ren, S Yu, H Pan, T Li, S Ge, J Zhang, N Xia - International journal of …, 2020 - mdpi.com
Precise gene editing is—or will soon be—in clinical use for several diseases, and more
applications are under development. The programmable nuclease Cas9, directed by a single-…

[HTML][HTML] A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

…, J Xia, H Xiong, X Yu, Q Qi, X Yu, L Li, H Yu, N Xia… - Cell research, 2020 - nature.com
Dear Editor, Since the beginning of this century, humanity has been struck three times by the
coronavirus outbreak. The most recent one is caused by the SARS-CoV-2 virus, which was …

Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody

…, A Kumar, K Modjarrad, Z Zheng, M Zhao, N Xia… - Science, 2013 - science.org
The prefusion state of respiratory syncytial virus (RSV) fusion (F) glycoprotein is the target of
most RSV-neutralizing activity in human sera, but its metastability has hindered …

[HTML][HTML] A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy

…, L Zhang, X Liu, P Lv, X Wang, W Luo, N Xia… - Nature …, 2022 - nature.com
The strategy of combining a vaccine with immune checkpoint inhibitors has been widely
investigated in cancer management, but the complete response rate for this strategy is still …

A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters

…, H Zhu, Q Zhao, Q Yuan, Y Guan, N Xia - Science translational …, 2021 - science.org
Multiple safe and effective vaccines that elicit immune responses against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary to respond to the ongoing …

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

Q Zhao, S Li, H Yu, N Xia, Y Modis - Trends in biotechnology, 2013 - cell.com
Human vaccines against three viruses use recombinant virus-like particles (VLPs) as the
antigen: hepatitis B virus, human papillomavirus, and hepatitis E virus. VLPs are excellent …

[HTML][HTML] Recent progress on the versatility of virus-like particles

…, J Chen, T Li, Q Zheng, H Yu, Y Gu, S Li, N Xia - Vaccines, 2020 - mdpi.com
Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural
proteins of a virus in the absence of genetic material. Having similar morphology to natural …

[HTML][HTML] Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound

…, J Jia, J Hou, MA McCrae, Z Gao, H Ren, N Xia… - Journal of …, 2016 - Elsevier
Background & Aims Hepatitis B virus (HBV) RNA in serum has recently been linked to
efficacy and prognosis of chronic hepatitis B (CHB) treatment. This study explored the nature, …